Mail

UK markets closed

NIKKEI 225
37,552.16
+113.55(+0.30%)
HANG SENG
16,828.93
+317.24(+1.92%)
CRUDE OIL
83.42
+0.06(+0.07%)
GOLD FUTURES
2,335.80
-6.30(-0.27%)
DOW
38,503.69
+263.71(+0.69%)
Bitcoin GBP
53,346.60
-308.99(-0.58%)

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

Cellectis SA (ZVA.BE)

Berlin - Berlin Delayed price. Currency in EUR

Add to watchlist

2.1660

0.0000

(0.00%)

At close: 09:04AM CEST

Full screen

Previous close	2.1660
Open	2.1660
Bid	2.1140 x 0
Ask	2.3140 x 0
Day's range	2.1660 - 2.1660
52-week range	2.1660 - 2.1660
Volume	500
Avg. volume	0

Market cap	N/A
Beta (5Y monthly)	N/A
PE ratio (TTM)	N/A
EPS (TTM)	N/A
Earnings date	N/A
Forward dividend & yield	N/A (N/A)
Ex-dividend date	N/A
1y target est	N/A

All

News

Press releases

GlobeNewswire
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
This novel editing approach might unlock new strategies for the treatment of metabolic and neurological diseasesNon-viral circular ssDNA delivery associated to TALEN® gene editing allows high levels of gene insertion in long-term repopulating HSPCs NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, will pres
GlobeNewswire
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new research paper in Molecular Therapy, demonstrating that TALEN-mediated intron editing of hematopoietic stem and progenitor cells (HSPCs) enables transgene expression restricted to the myeloid lineage. This approach co
GlobeNewswire
Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that preliminary data exploring novel TALEN® editing process in hematopoietic stem and progenitor cells (HSPCs) will be presented at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, to be held in Baltimore, Maryland,

NIKKEI 22537,552.16+113.55(+0.30%)

HANG SENG16,828.93+317.24(+1.92%)

CRUDE OIL83.42+0.06(+0.07%)

GOLD FUTURES2,335.80-6.30(-0.27%)

DOW38,503.69+263.71(+0.69%)

Bitcoin GBP53,346.60-308.99(-0.58%)

What is the true cost of the UK state pension?

Cellectis SA (ZVA.BE)

Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs

Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs

Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting

NIKKEI 225
37,552.16
+113.55(+0.30%)

HANG SENG
16,828.93
+317.24(+1.92%)

CRUDE OIL
83.42
+0.06(+0.07%)

GOLD FUTURES
2,335.80
-6.30(-0.27%)

DOW
38,503.69
+263.71(+0.69%)

Bitcoin GBP
53,346.60
-308.99(-0.58%)